SAFETY AND EFFICACY OF PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 INHIBITORS AFTER ACUTE CORONARY SYNDROME; A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

被引：0
|
作者：
Atia, A. [1 ,2 ]
Wageeh, A. [3 ]
Aboeldahab, H. [4 ]
Elneny, M. [5 ]
Abdelwahab, M. [6 ]
Elmallahy, M.
Aboelkhier, M. [7 ,8 ]
Elawfi, B. [9 ]
Sayed, S. [10 ]
Elrosasy, A. [1 ]
机构：
[1] Cairo Univ, Cardiol, Fac Med, Cairo, Egypt
[2] Med Res Grp Egypt, Cardiol, Cairo, Egypt
[3] Menoufia Univ, Cardiol, Fac Med, Menoufia, Egypt
[4] Alexandria Univ, Med Res Inst, Biomed Informat & Med Stat Dept, Biomed Informat & Med Stat, Alexandria, Egypt
[5] Al Azhar Univ, Damietta Fac Med, Cardiol, Dumyat, Egypt
[6] Helwan Univ, Cardiol, Fac Med, Cairo, Egypt
[7] Tanta Univ, Cardiol, Fac Med, Tanta, Egypt
[8] Suez Canal Univ, Master Program, Sci, Fac Sci, Ismailia, Egypt
[9] Sanaa Univ, Cardiol, Fac Med, Sanaa, Yemen
[10] Minia Univ, Cardiol, Fac Med, Al Minya, Egypt
来源：
ATHEROSCLEROSIS | 2023年 / 379卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P248
引用
收藏
页码：S78 / S80
页数：2
相关论文
共 50 条
  • [41] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression
    Raccah, Bruria Hirsh
    Yanovsky, Alona
    Treves, Nir
    Rotshild, Victoria
    Renoux, Christel
    Danenberg, Haim
    Eliaz, Ran
    Matok, Ilan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 335 : 7 - 14
  • [42] Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome
    Mensink, F. B.
    Los, J.
    Ten Cate, T. J. F.
    Oemrawsingh, R. M.
    Brouwer, M. A.
    El Messaoudi, S.
    van Royen, N.
    Cornel, J. H.
    Riksen, N. P.
    van Geuns, R. J. M.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [43] Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis
    Matin, Abdul
    Chaudhry, Gul-e-Saba
    Azra, Mohamad Nor
    Gazli, Mohamad
    Sung, Yeong Yik
    Muhammad, Tengku Sifzizul TENGku
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2024, 31 (04): : 14 - 34
  • [44] Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
    Sahebkar, A.
    Simental-Menda, L. E.
    Guerrero-Romero, F.
    Golledge, J.
    Watts, G. F.
    DIABETES OBESITY & METABOLISM, 2015, 17 (11): : 1042 - 1055
  • [45] Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
    Zhao, Jiajing
    Tong, Xinyu
    Peng, Jian
    Lyu, Chuxin
    Lu, Shu
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (03)
  • [46] Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis
    Yu, Zongliang
    Hu, Lanqing
    Sun, Changxin
    Wang, Zeping
    Zhang, Xiaonan
    Wu, Min
    Liu, Longtao
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (06) : 445 - 453
  • [47] Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice
    Gayoso-Rey, Monica
    Diaz-Trastoy, Olaia
    Yaiza Romero-Ventosa, Elena
    Garcia-Beloso, Nerea
    Gonzalez-Freire, Lara
    Lorenzo-Lorenzo, Karina
    Mantinan-Gil, Beatriz
    Palmeiro-Carballeira, Regina
    Bravo-Amaro, Marisol
    del Mar Lopez-Gil-Otero, Maria
    Martinez-Reglero, Cristina
    Crespo-Diz, Carlos
    Fernandez-Catalina, Pablo
    Pineiro Corrales, Guadalupe
    CLINICAL THERAPEUTICS, 2021, 43 (04) : E111 - E121
  • [48] Efficacy and Safety Data on Novel Oral Proprotein Convertase Subtilisin-Kexin Type 9 Antagonist
    Elshourbagy, Nabil A.
    Godugu, Kavitha
    Fujioka, Kazutoshi
    Li, Weikun
    Meyers, Harold V.
    Abdel-Meguid, Sherin S.
    Mousa, Shaker A.
    CIRCULATION RESEARCH, 2019, 125 (12) : E110 - E110
  • [49] Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia
    Li, Bin
    Hao, Pan-Pan
    Zhang, Yong
    Yin, Rui-Hong
    Kong, Qing-Zan
    Cai, Xiao-Jun
    Zhao, Zhuo
    Qi, Jian-Ni
    Li, Ying
    Xiao, Jie
    Wang, Fu
    Yi, Wei
    Ji, Xiao-Ping
    Su, Guo-Hai
    ONCOTARGET, 2017, 8 (18) : 30455 - 30463
  • [50] Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis
    Dobrzynski, Jeanne M.
    Kostis, John B.
    Sargsyan, Davit
    Zinonos, Stavros
    Kostis, William J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 728 - 733
12345